Trials / Unknown
UnknownNCT05488860
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases: A Pilot Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
Piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. Mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. And the addition of ultrasound technique improves the effectiveness of microneedling. Investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases.
Detailed description
Piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. Mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. And the addition of ultrasound technique improves the effectiveness of microneedling. Investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases. Investigators accept participants of hypertrophic scar, keloid and warts. For participants who are not candidates for traditional surgery, investigators will consider to accept carefully.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triamcinolone acetonide(scar)/5-ALA(others) | For scar, the drug is triamcinolone acetonide. |
| PROCEDURE | Piezoelectric drived microneedling | Piezoelectric drived microneedling |
| DRUG | 5-ALA (a photosensitizer for photodynamic therapy). | For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy). |
Timeline
- Start date
- 2022-07-30
- Primary completion
- 2024-06-30
- Completion
- 2024-07-31
- First posted
- 2022-08-05
- Last updated
- 2022-08-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05488860. Inclusion in this directory is not an endorsement.